Chronic Myeloid Leukemia

Brian Druker, MD

Prince Mahidol Award Conference

February 1, 2019
Chronic Myeloid Leukemia (CML)

- 15 - 20% of all leukemias
- 1 - 2 cases per 100,000 per year

Average age of onset - 50 to 60 yrs of age

Median survival – 3 to 5 years
BCR-ABL As a Therapeutic Target for CML

Bcr-Abl Tyrosine Kinase

Substrate

CML

ATP → ADP

PO₄

STI571

ATP

CML
'STI571 (CGP 57148B)
Imatinib mesylate
Gleevec™, Glivec®
CML Summary

- There are currently 5 drugs on the market that target BCR-ABL
CML Summary

- There are currently 5 drugs on the market that target BCR-ABL
CML Summary

- There are currently 5 drugs on the market that target BCR-ABL

- Survival has been significantly prolonged
CML Life Expectancy

Since 2009 we have been working with the premise

“The improved survival in CML... is so dramatic that these new agents must be made available... As rapidly as possible throughout the whole world.”
As we look to the future

*CML is predicted to become the most prevalent leukaemia by 2040 when there are projected to be over 3 million patients worldwide.*
Global programs impact CML education, access to diagnostics and therapy

Enhancing patients survival around the world
Our mission is to increase global access to treatment, care and support for people living with cancer.

In memory of Max Rivarola, 1973-1991
The Max Access Solution Model
A patient centered system of humanitarian access to oncology treatment

PATIENT SUPPORT
A support system around the patient

HEALTHCARE PROVIDERS
An approved network of cancer specialists

LOGISTICS & DISTRIBUTION
End to end validated supply chain

TREATMENT ACCESS
Procurement of quality targeted treatment
Max Access Solution for CML

- 72 countries
- 30,000 CML patients on treatment
- 600 physicians
- 3 distribution centers
- 70 Patient associations